Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany

BACKGROUND: Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Bjoern, Luebke, Nadine, Feldt, Torsten, Keitel, Verena, Brandenburger, Timo, Kindgen-Milles, Detlef, Lutterbeck, Matthias, Freise, Noemi F, Schoeler, David, Haas, Rainer, Dilthey, Alexander, Adams, Ortwin, Walker, Andreas, Timm, Joerg, Luedde, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278033/
https://www.ncbi.nlm.nih.gov/pubmed/34278371
http://dx.doi.org/10.1016/j.lanepe.2021.100164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278033/
https://www.ncbi.nlm.nih.gov/pubmed/34278371
http://dx.doi.org/10.1016/j.lanepe.2021.100164

Ejemplares similares